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http://www.trialsjournal.com/content/14/1/100STUDY PROTOCOL Open AccessVitamin D to prevent acute lung injury following
oesophagectomy (VINDALOO): study protocol for
a randomised placebo controlled trial
Dhruv Parekh1,2, Rachel C A Dancer1, Sian Lax1, Mark S Cooper1, Adrian R Martineau3, William D Fraser4,
Olga Tucker1, Derek Alderson1, Gavin D Perkins2, Fang Gao-Smith1 and David R Thickett1*Abstract
Background: Acute lung injury occurs in approximately 25% to 30% of subjects undergoing oesophagectomy.
Experimental studies suggest that treatment with vitamin D may prevent the development of acute lung injury by
decreasing inflammatory cytokine release, enhancing lung epithelial repair and protecting alveolar capillary barrier
function.
Methods/Design: The ‘Vitamin D to prevent lung injury following oesophagectomy trial’ is a multi-centre,
randomised, double-blind, placebo-controlled trial. The aim of the trial is to determine in patients undergoing
elective transthoracic oesophagectomy, if pre-treatment with a single oral dose of vitamin D3 (300,000 IU (7.5 mg)
cholecalciferol in oily solution administered seven days pre-operatively) compared to placebo affects biomarkers of
early acute lung injury and other clinical outcomes. The primary outcome will be change in extravascular lung
water index measured by PiCCOW transpulmonary thermodilution catheter at the end of the oesophagectomy. The
trial secondary outcomes are clinical markers indicative of lung injury: PaO2:FiO2 ratio, oxygenation index;
development of acute lung injury to day 28; duration of ventilation and organ failure; survival; safety and tolerability
of vitamin D supplementation; plasma indices of endothelial and alveolar epithelial function/injury, plasma
inflammatory response and plasma vitamin D status. The study aims to recruit 80 patients from three UK centres.
Discussion: This study will ascertain whether vitamin D replacement alters biomarkers of lung damage following
oesophagectomy.
Trial registration: Current Controlled Trials ISRCTN27673620
Keywords: Acute lung injury, One lung ventilation, Oesophagectomy, Vitamin DBackground
Acute lung injury (ALI) and the more severe acute respira-
tory distress syndrome (ARDS) are common, devastating
clinical syndromes of acute respiratory failure in the critic-
ally ill person. The incidence of ALI is 79 per 100,000 per-
son years with a mortality rate of 30% to 65% [1].
Survivors of ARDS experience a significant reduction in
health-related quality of life, with 46% reported to be un-
able to return to work within 12 months.* Correspondence: d.thickett@bham.ac.uk
1College of Medical and Dental Sciences, University of Birmingham, Vincent
Drive, Birmingham B15 2TT, UK
Full list of author information is available at the end of the article
© 2013 Parekh et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orALI is the final common pathway of response to a var-
iety of direct pulmonary insults, such as bacterial /viral
pneumonia and gastric aspiration, or indirect insults,
such as abdominal sepsis or battlefield trauma. Only a
relatively small proportion of patients develop ALI, with
research suggesting that genetic, demographic (age), so-
cial (smoking, alcohol abuse) and other factors play a
role in determining who develops ALI [1,2]. There are
no current readily available tests that can clearly identify
those who are at high risk of ALI and no therapeutic in-
terventions proven to prevent its occurrence.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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To allow access to the oesophagus during surgery (using
the transthoracic technique), one of the lungs is deflated
and the subject is ventilated through the other lung. This
is known as one-lung ventilation (OLV). There is a high
postoperative incidence of ALI/ARDS [3-5] following
OLV and unlike most insults leading to lung injury the
delivery of OLV is predictably timed, thereby allowing
serial studies to be carried out throughout the period of
stimulus and development of the condition. Preoperative
risk factors including age, respiratory function and
cigarette smoking have been found to be related to the
incidence of postoperative pulmonary complications
[3,6-8]. It is unclear at present why only a percentage of
patients undergoing OLV develop lung injury or why the
lung injury typically occurs 24 to 48 hours after the ces-
sation of OLV. Our data show that the development of
lung injury is, however, associated with a doubling of in-
hospital stay and elevated mortality.
We have extensively modeled the local and systemic in-
flammatory response to transthoracic oesophagectomy in
50 patients undergoing OLV. After OLV, patients have a
neutrophilic alveolitis, with a significant alveolar and sys-
temic inflammatory response. This is associated with the
release of markers of both endothelial and alveolar epithe-
lial dysfunction and an increase in the permeability of the
alveolar barrier. This manifests clinically as increased
extravascular lung water and a fall in oxygenation.
Alveolar levels of surfactant protein D and bronchoal-
veolar lavage fluid (BALF) protein permeability index are
highest in those who develop ALI within 72 hours of
OLV suggesting that peri-operative alveolar epithelial
damage is a risk factor for the subsequent development
of ALI. Immediate post-operative plasma markers of
neutrophilic activation (myeloperoxidase, and matrix
metalloproteinase-9 (MMP-9)) as well as the receptor
for advanced glycation end-products (RAGE, a type I
epithelial cell marker) are similarly raised in those who
develop ALI within 72 hours of OLV. Proposed causative
mechanisms for this injury include the ischaemic/reper-
fusion insult suffered by the collapsed lung, as well as
oxidative stress and barotrauma causing epithelial injury
to the ventilated lung [9]. These mechanisms are import-
ant in the pathogenesis of ALI making OLV a valid
model for studying the pathogenesis of ALI in humans
and exploring therapeutic strategies for preventing lung
injury in a predefined subject population [10,11].
Vitamin D biology
Vitamin D3, or cholecalciferol, is mainly formed in the skin
after exposure to sunlight, then hydroxylated in the liver to
25-hydroxyvitamin D3 (25(OH)D3) and subsequently in the
kidney to 1,25-dihydroxyvitamin D3 (1,25(OH)2D3). When
25(OH)D3 is sufficiently available, 24,25-dihydroxyvitaminD3 (24,25(OH)2D3) is formed in the kidney which is further
catabolised. Vitamin D metabolites are bound in the circu-
lation to vitamin D binding protein (VDBP) which has a
high affinity for 25(OH)D3, 24,25(OH)2D3 and 1,25(OH)
2D3 and, therefore, regulates free circulating concentrations
of vitamin D metabolites. The biologically active metabolite
1,25(OH)2D3 can also be generated locally within tissues
due to induction of extra-renal cyp27b1 (25(OH)D-1-alpha
hydroxylase) and binds to the vitamin D receptor (VDR)
resulting in modified gene expression.
Epidemiological studies have suggested a role for low
vitamin D status in the risk of developing both viral and
bacterial infection [12,13]. A recent study has further
demonstrated the pleiotropic anti-inflammatory effects of
vitamin D in patients with pulmonary tuberculosis [14].
Published data suggest that vitamin D deficiency is com-
mon in critically ill patients [15], and recent prospective
studies suggest an association with increased morbidity
and mortality [16-18]. Literature on acute vitamin D sup-
plementation in critical illness is lacking but serious ad-
verse events attributable to vitamin D supplementation
are rare [18,19].
Is severe vitamin D deficiency a driver of post-OLV ALI?
Vitamin D has profound effects on human immunity act-
ing as an immune system modulator, preventing excessive
expression of inflammatory cytokines and increasing the
‘oxidative burst’ potential of macrophages, thereby enhan-
cing bacterial killing. Vitamin D also stimulates the release
of antimicrobial peptides such as LL-37 (cathelicidin)
within the lung. LL-37 can also bind to and neutralize lipo-
polysaccharide (LPS), and functions as a chemoattractant
for neutrophils, monocytes and T cells through a formyl
peptide receptor-like molecule [20].
Respiratory epithelial cells convert 25(OH)D3 to 1,25
(OH)2D3 and activate VDR responsive genes increasing
the production of hCAP18 from which LL-37 is cleaved
within 24 hours [21]. In terms of the pathophysiology of
ALI this could be important as LL-37 may drive epithelial
repair responses as well as being an anti-microbial peptide
[22]. Elevating local LL-37 may also be important as a
downstream immunomodulator of vitamin D since it has
recently been shown to reduce Toll-like receptor (TLR)
agonist-mediated neutrophil-derived increases in IL-1β, IL-
6, IL-8 and tumour necrosis factor-alpha (TNF-α) in
addition to stimulating bacterial phagocytosis [23]. The
ability of 1,25(OH)2D3 to directly inhibit nuclear factor-
kappaB (NF-kb) signalling and suppress macrophage TLR
expression suggests that vitamin D may also play a key role
as a feedback regulator of macrophage responses [24,25].
The only study looking at vitamin D levels in patients
with severe sepsis suggests that these patients have a lower
serum vitamin D level than healthy control patients. This
was associated with lower plasma levels of LL-37,
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in vivo [26]. IL-1 and TNF production induced by TLR3 ag-
onists from monocyte derived macrophages are inhibited to
the same extent by 25(OH)D3 and 1,25(OH)2D3 after 24 -
hours suggesting that the vitamin D metabolites may have
a rapid anti-inflammatory action and that local intracrine
activation of 25(OH)D3 can be anti-inflammatory [27].
Recent data have further implicated vitamin D in adap-
tive immunity because of its influence upon the differenti-
ation of T cells between the regulatory T cell (Treg) and the
pro-inflammatory T helper 17 (Th17) subsets [28-30]. Th17
cells are known to stimulate tissue inflammation and neu-
trophil chemotaxis, both of which are seen in ALI, pre-
dominantly by IL-17 production. It also appears that
expression of markers of Treg cells (Foxp3) or Th17 cells
(IL-17) by T cells may not be stable and that there is a
greater degree of plasticity in their differentiation than pre-
viously appreciated [29]. Recent evidence has further sug-
gested Treg cells are important in the resolution of
experimental ALI. This suggests that local lung regulation
of the balance between Treg and Th17 cells may be a de-
terminant of resolution/persistence of neutrophilic inflam-
mation which is known to be associated with a poor
prognosis in human ALI.
Although the above suggest a potentially beneficial effect
of vitamin D, we must exercise some caution as some
studies have shown potentially adverse effects of vitamin
D. In low dose nasal LPS challenge, cellular inflammation
is actually lower in vitamin D receptor deficient (VDR
KO) mice due to toll-receptor hyporesponsiveness. In
addition the chemotactic effects of LL-37 could in theory
increase neutrophil recruitment to the lung; albeit in ALI,
CXCL-8 and ENA-78 are the main chemokines driving
neutrophil recruitment. More recently it has been shown
that the plasma LL-37 concentration was decreased in
vitamin D supplemented patients with tuberculosis, pos-
sibly representing a global suppressive effect of vitamin D
supplementation on markers of acute phase response or
an indirect response to enhanced microbial killing [14].
Despite these reservations, the predominant biological ef-
fects of vitamin D led us to hypothesise that vitamin D de-
ficiency may be a risk factor for ALI, causing elevated
inflammation which results in exaggerated epithelial dam-
age in at risk, vitamin D deficient individuals.
The VINDALOO trial is a three centre randomised
double blind, placebo-controlled trial aiming to define
the safety and effectiveness of a single high dose of vita-
min D in preventing ALI in a group of patients at high
risk of developing the condition.
Methods/Design
Trial approvals and conduct
The trial is approved by South Birmingham Research
Ethics Committee (REC 12/WM/0092). The trial isregistered on the International Standard Randomised
Controlled Trial Registry (ISRCTN27673620). The spon-
sor organisation for the trial is the University of Birming-
ham. The trial is funded by the Medical Research Council
UK (MRC reference G1100196). The trial will be carried
out in accordance with the Medical Research Council
(MRC) Good Clinical Practice Guidelines, applicable UK
legislation and Standard Operating Procedures of the Peri-
operative and Critical Care Trials Group at the University
of Birmingham. The trial will be reported in line with the
Consolidated Standards of Reporting Trials (CONSORT)
2010 guidelines [31].
Outcome measures
Primary outcome
The primary outcome will be the extravascular lung water
index (EVLWI) measured by PiCCO thermodilution cath-
eter at the end of the oesophagectomy (measured within
one hour post-operatively). In ALI the changes in lung
compliance that are a cardinal feature of this disease occur
due to the accumulation of extravascular lung water
(EVLW). The PiCCO EVLWI has been shown to be an in-
dependent risk factor for mortality in ALI and has been
used as the primary outcome in several clinical trials
in ALI (BALTI-1, HARP) [32,33] as well as post-
thoracotomy [34]. In BALTI-1 we demonstrated that the
transpulmonary thermodilution technique (PiCCO) is able
to detect a significant change in lung water with a treat-
ment that might be expected to achieve this objective. We
have tested the CV coefficient of variance of EVLWI mea-
surements previously and found it to be 6.8% over six se-
quential assessments over two hours. Further, we have
studied the perioperative changes in lung water following
oesophagectomy and demonstrated that preoperative vita-
min D status influences the level of accumulation of
EVLW.
Secondary outcomes
The trial secondary outcomes are clinical markers indicative
of lung injury: PaO2:FiO2 ratio, oxygenation index, develop-
ment of lung injury/ARDS during the first 28 days, venti-
lator and organ failure free days, survival (28 and 90 day)
and safety and tolerability of vitamin D supplementation.
Lung injury will be defined by the American European
Consensus Conference definition [35] as the acute onset
of: (1) bilateral infiltrates on the chest x-ray; (2) hypox-
aemia with a PaO2:FiO2 ratio of <40 kPa; and (3) ab-
sence of clinical evidence of left atrial hypertension.
Ventilator free days are defined in accordance with the
ARDSnet criteria as the number of calendar days after
initiating unassisted breathing to day 28 after random-
isation, assuming a patient survives for at least 48 con-
secutive hours after initiating unassisted breathing [36].
Un-assisted breathing is defined as one of at least 48
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nasal prong oxygen, or room air; (2) T-tube breathing; and
(3) tracheostomy mask breathing, CPAP = 5 cm H20 with-
out pressure support of intermittent mandatory ventila-
tion assistance.
Organ failure free days are defined in a similar manner
to ventilator free days with an organ failure free day being
a day without evidence of non-respiratory organ failure.
Organ failure will be defined as a sequential organ failure
assessment (SOFA) score of greater than three [37].
Plasma indices of endothelial and alveolar epithelial
function/injury, plasma inflammatory response will be
measured by ELISA. Plasma vitamin D status (25(OH)
D3, 1,25(OH)2D3, VDBP) and calcium will be assessed
peri-operatively (pre-drug dose, pre-operative, post-
operative, day 1 and day 3) as well as EVLWI day 1
post-operatively (measured at 9 am on day 1).
Eligibility criteria
Patients will be eligible for the trial if they fulfill the fol-
lowing criteria:
 Planned transthoracic oesophagectomy for
oesophageal carcinoma at a participating centre.
 Men over 18 years old on the day of first dose of the
investigational medicinal product (IMP)
 Women over the age of 55 or more than 2 years
since menopause.
 Women of potential child bearing age (under 55 and
less than two years since menopause) may be
recruited provided they agree to use contraception
during the pre-post-operative period (eight weeks).
 Ability to give written informed consent to
participate in the study.
Patients fulfilling any of the criteria below will be
excluded:
 Known intolerance of vitamin D.
 Known sarcoidosis, hyperparathyroidism, or
nephrolithiasis.
 Known serum corrected calcium >2.65 mmol/L.
 Undergoing haemodialysis.
 Pregnant or breastfeeding.
 Patients with tuberculosis or lymphoma.
 Diagnosis of chronic obstructive pulmonary disease
(COPD) with a forced expiratory volume in one
second (FEV1) less than 50% predicted or resting
oxygen saturations of less 92%.
Power and sample size estimate
There are no direct data to predict the effect size of vita-
min D replacement upon EVLWI. In our preliminary
work with 50 patients, the patients with 25(OH)D3concentrations less than 15 nmol/L had the greatest in-
creases in EVLWI (+3.2 ml/kg, +27%) compared to those
patients with less severe deficiency pre–postoperatively
(+1.0 ml/kg, +10% P = 0.013) suggesting that severe vita-
min D deficiency influences EVLWI. As a group, after
undergoing oesophagectomy our patients have a mean
post-operative EVLWI of 10.1 ml/kg and standard devi-
ation of 2.9 ml/kg. For the study to be able to detect a
change of 20% in EVLWI with a power of 80% we will re-
quire approximately 34 patients in each arm to reach the
primary endpoint (P = 0.05). An additional six patients will
be needed to allow for dropouts, such as open/close cases,
unexpected deaths and other difficulties with data collec-
tion. Thus, we intend to recruit 40 patients to each arm of
the study.
With 34 patients completing each arm of the study,
based upon preliminary unpublished data from 50
oesophagectomy cases, this study would detect a treatment
effect of vitamin D upon the PO2:FiO2 ratio postoperative
(PO) of ± 8.16 (± 20%), PO plasma soluble intercellular ad-
hesion molecule-1 (sICAM-1) of ± 16 ng/ml (± 32%),
plasma C-reactive protein (CRP) ± 53 ng/ml (± 33%), PO
plasma von Willebrand factor (vWF) ± 55% relative to con-
trol plasma (± 24.7% change), PO plasma high-mobility
group box 1 (HMGB-1) 5.42 ng/ml (± 54%), PO plasma
myeloperoxidase (MPO) 105 pg/ml (± 57%), PO plasma
MMP-9 51 ng/ml (± 57%), and PO plasma surfactant
protein-D (SP-D) 691 ng/ml (± 61%). All calculations as-
sume 80% power at a two-tailed significance level of 0.05.
Trial conduct
Approach to patients and obtaining informed consent
Patients will be identified through upper gastrointestinal
cancer teams. Eligible patients will be invited to partici-
pate by their treating clinician, specialist clinical nurse or
research nurse. If agreeable, written informed consent
will be obtained, following a face to face discussion about
the study.
Randomisation and drug / placebo supply
The trial drug manufacturer will produce the randomisa-
tion sequence using a block size of 10 with equal alloca-
tion between active and placebo groups. Drug (oral
cholecalciferol oily solution Vigantol, 300,000 IU (7.5 mg))
and matching placebo (Miglyol 812 oil, the vehicle for
vitamin D3 in Vigantol) will be supplied and packaged
according to the randomisation sequence into numbered
treatment boxes by Novalabs (Leicester, UK). Drug boxes
will be supplied to centres in blocks of 10 thus ensuring
an equal allocation between active and placebo groups to
balance any differences in case mix, pre-operative, opera-
tive and post-operative care between centres. Patients will
be randomised sequentially by allocating them to the next
numbered treatment pack held at the centre.
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Subjects will receive either 300,000 IU (7.5 mg) of vitamin
D or placebo seven days prior to planned oesophagectomy.
The drug will be administered by qualified medical or
nursing staff.
Concomitant medications
Patients taking the following medications are not eligible
for inclusion in the study:
 Taking more than 1,000 IU/day (25 mcg/day)
vitamin D supplementation by month preceding
enrolment.
 Taking cardiac glycoside, carbamazepine,
phenobarbital, phenytoin, primidone or long-term
immunosuppressant therapy.
 Patients taking benzothiadiazine derivatives at doses
higher than that which is recommended in the
British National Formulary (BNF).
 Patients taking a benzothiadiazine derivative in
combination with a calcium supplement.
Post randomisation withdrawals and exclusions
Subjects may withdraw from the trial or the trial treat-
ment at any time without prejudice. If a subject with-
draws from the trial treatment, then they will be
followed-up wherever possible and data collected as per
protocol until the end of the trial. The only exception to
this is where the subject also explicitly withdraws con-
sent for follow-up.
Blinding/un-blinding
Patients, clinical and research / trial staff will be unaware
of the arm of the study to which a patient is allocated. Ac-
tive and placebo treatment packs and their contents will
be identical in appearance. The protocol allows for emer-
gency un-blinding in the event of significant concerns
about patient safety. In the unlikely event that un-blinding
is required the local investigator will discuss this with the
Chief Investigator. All events will be logged.
Monitoring and reporting adverse events
VINDALOO is recruiting a population who are prone to
recognized medical and surgical complications. It is
expected that many of the patients will experience an
event that might be seen as a serious adverse event but
is a recognized complication following oesophagectomy.
Adverse and serious adverse events which are recognised
complications of surgery, for example, medical (pneumo-
nia, sepsis) and surgical (chyle leak, anastamosis leak)
will be recorded in the case report form.
Death and other serious adverse events thought to be
related to the study drug or serious unexpected serious
adverse reactions will be reported to the trial co-ordinating centre and Chief Investigator within 24 hours
of becoming aware of their occurrence. The Chief Investi-
gator will inform the sponsor and regulatory authorities.
Data collection
Data up until hospital discharge will be recorded in each
subject's Case Report Form (CRF) by a member of the
trials team. Most of the data collected will be obtained
from the patient’s hospital notes. In the unlikely event
that a subject is transferred to another hospital, the
study team will ensure that data collection is completed
by the receiving hospital.
If the subject remains in hospital at 28 or 90 days, sur-
vival at these time points will be recorded by hospital
staff. Mortality after hospital discharge will be obtained
from the National Health Service (NHS) Statistical Tra-
cing Service (NSTS).
Statistical analysis plan
Data will be analysed with the help of the trial statistician.
Data will be analysed using SPSS for Windows 17.0. A de-
tailed analysis plan will be developed during the trial prior
to commencement of analysis. In brief, for continuously
distributed data, differences between groups will be tested
using independent samples t-tests with transformations of
variables to Normality if appropriate, or non-parametric
equivalents. Chi-squared tests (or Fisher’s Exact tests) will
be used for categorical variables. A P value of 0.05 will be
considered as significant. We will test for significant corre-
lations between changes in the biological markers using
standard methods. The treatment effect will be analysed
on an intention-to-treat basis. For further examinations of
relationships between a binary variable and known ex-
planatory variables, the following tests will be applied as
appropriate. Logistic regression will be used to provide the
estimated risk ratios for the treatment effect with associ-
ated 95% confidence interval (CI) . Time to event out-
comes, such as duration of ventilation or duration of
hospital stay, will be analysed by survival methods and
reported as hazard ratios and 95% CI. A single final ana-
lysis is planned at the end of the trial.
Trial organisation/oversight
Trial oversight will be provided by a Trial Steering Com-
mittee (TSC) comprising investigators, clinicians and
trialists. An independent data monitoring committee will
monitor the safety of participants enrolled in the trial
through regular review of adverse event reports. An in-
terim analysis of efficacy is not planned.
Discussion
The preliminary data that this study is based upon sug-
gests a significant role for vitamin D deficiency as a risk
factor for the development of acute lung injury. This
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and inflammation to determine the proof of concept that
vitamin d replacement may have efficacy as a preventa-
tive agent for the development of acute lung injury.
Trial status
Patient recruitment commenced in September 2012 and
is expected to run for two years (last patient recruited in
August 2014).
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